Verastem Oncology Announces Appointment of John Hayslip, M.D., to Chief Medical Officer
April 18 2024 - 4:05PM
Business Wire
Dr. Hayslip to lead development programs for
avutometinib, including Verastem Oncology’s international
confirmatory Phase 3 RAMP 301 clinical trial, and advance pipeline
assets
Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company
committed to advancing new medicines for patients with cancer,
today announced the appointment of John Hayslip, M.D., an
accomplished oncologist with deep clinical research, development,
and commercialization experience, to chief medical officer where he
will lead the Company’s clinical and medical strategy. Dr. Hayslip
succeeds Louis J. Denis, M.D., who recently departed the
company.
“John is a recognized leader in oncology with broad expertise
across cancer research and development, business development and
organizational leadership, and we welcome him to the Verastem
team,” said Dan Paterson, president and chief executive officer of
Verastem Oncology. “John’s extensive experience will be integral as
we advance our clinical programs focused on RAS/MAPK pathway-driven
cancers, such as low-grade serous ovarian cancer, pancreatic cancer
and lung cancer, while also submitting our rolling NDA submission
for the avutometinib and defactinib combination in low-grade serous
ovarian cancer, planned in the first half of this year.”
Dr. Hayslip has more than 25 years of oncology and research and
development experience across industry and academia, most recently
serving as the chief medical officer at I-MAB Biopharma. Prior to
that, Dr. Hayslip was the vice president of clinical development at
Nektar Therapeutics and led clinical development activities for
multiple therapies while at AbbVie Oncology. Prior to joining
AbbVie Oncology, Dr. Hayslip served as the chief of hematology and
bone marrow transplant and the director of clinical research and
data management at the University of Kentucky’s Markey Cancer
Center, where he led numerous cancer research studies. Dr. Hayslip
received his medical degree from Northeast Ohio Medical University
and a master’s degree in clinical research from the Medical
University of South Carolina. Following his residency in internal
medicine, Dr. Hayslip completed his fellowship in
hematology-oncology at the Medical University of South Carolina,
leading to dual board certifications in both hematology and medical
oncology. He holds multiple U.S. and international patents and has
published dozens of scientific papers and reviews in renowned
journals including Lancet Haematology, Clinical Cancer Research,
Leukemia Research, Blood, and Journal of Clinical Oncology.
“I am excited to join Verastem Oncology and I look forward to
working with the team to potentially bring a much-needed new
treatment option to patients with low-grade serous ovarian cancer
in the near term,” said Dr. Hayslip. “I believe the company’s novel
approach of addressing both the RAS signaling pathway and key
mechanism of intrinsic and acquired resistance offers a promise of
better outcomes for patients living with RAS/MAPK pathway-driven
cancers and beyond.”
About Verastem Oncology
Verastem Oncology (Nasdaq: VSTM) is a late-stage development
biopharmaceutical company committed to the development and
commercialization of new medicines to improve the lives of patients
diagnosed with cancer. Our pipeline is focused on novel small
molecule drugs that inhibit critical signaling pathways in cancer
that promote cancer cell survival and tumor growth, including
RAF/MEK inhibition and FAK inhibition. For more information, please
visit www.verastem.com and follow us on LinkedIn.
Forward-Looking Statements Notice
This press release includes forward-looking statements about
Verastem Oncology’s strategy, future plans and prospects, including
statements related to the expected timing of the planned rolling
New Drug Application (NDA) submission for the avutometinib and
defactinib combination in low-grade serous ovarian cancer, the
potential for and timing of commercialization of product candidates
and potential for additional development programs involving
Verastem Oncology’s lead compound. The words "anticipate,"
"believe," "estimate," "expect," "intend," "may," "plan,"
"predict," "project," "target," "potential," "will," "would,"
"could," "should," "continue," “can,” “promising” and similar
expressions are intended to identify forward-looking statements,
although not all forward-looking statements contain these
identifying words. Forward-looking statements are not guarantees of
future performance and are subject to risks and uncertainties that
could cause actual results to differ materially from those
expressed or implied in such statement.
Applicable risks and uncertainties include the risks and
uncertainties, among other things, regarding: the success in the
development and potential commercialization of our product
candidates, including avutometinib in combination with other
compounds, including defactinib, LUMAKRAS™ and others; the
uncertainties inherent in research and development, such as
negative or unexpected results of clinical trials, the occurrence
or timing of applications for our product candidates that may be
filed with regulatory authorities in any jurisdictions; whether and
when regulatory authorities in any jurisdictions may approve any
such applications that may be filed for our product candidates,
and, if approved, whether our product candidates will be
commercially successful in such jurisdictions; our ability to
obtain, maintain and enforce patent and other intellectual property
protection for our product candidates; the scope, timing, and
outcome of any legal proceedings; decisions by regulatory
authorities regarding trial design, labeling and other matters that
could affect the timing, availability or commercial potential of
our product candidates; whether preclinical testing of our product
candidates and preliminary or interim data from clinical trials
will be predictive of the results or success of ongoing or later
clinical trials; that the timing, scope and rate of reimbursement
for our product candidates is uncertain; that third-party payors
(including government agencies) may not reimburse; that there may
be competitive developments affecting our product candidates; that
data may not be available when expected; that enrollment of
clinical trials may take longer than expected; that our product
candidates will cause adverse safety events and/or unexpected
concerns may arise from additional data or analysis, or result in
unmanageable safety profiles as compared to their levels of
efficacy; that our product candidates may experience manufacturing
or supply interruptions or failures; that any of our third party
contract research organizations, contract manufacturing
organizations, clinical sites, or contractors, among others, who we
rely on fail to fully perform; that we face substantial
competition, which may result in others developing or
commercializing products before or more successfully than we do
which could result in reduced market share or market potential for
our product candidates; that we will be unable to successfully
initiate or complete the clinical development and eventual
commercialization of our product candidates; that the development
and commercialization of our product candidates will take longer or
cost more than planned, including as a result of conducting
additional studies; that we may not have sufficient cash to fund
our contemplated operations; that we may not attract and retain
high quality personnel; that we or Chugai Pharmaceutical Co., Ltd.
will fail to fully perform under the avutometinib license
agreement; that our target market for our product candidates might
be smaller than we are presently estimating; that Secura Bio, Inc.
will fail to fully perform under the asset purchase agreement with
Secura Bio, Inc., including in relation to milestone payments; that
we will not see a return on investment on the payments we have and
may continue to make pursuant to the collaboration and option
agreement with GenFleet or that GenFleet will fail to fully perform
under the agreement; that we may be unable to obtain adequate
financing in the future through product licensing, co-promotional
arrangements, public or private equity, debt financing or
otherwise; that we will not pursue or submit regulatory filings for
our product candidates; and that our product candidates will not
receive regulatory approval, become commercially successful
products, or result in new treatment options being offered to
patients.
Other risks and uncertainties include those identified under the
heading “Risk Factors” in the Company’s Annual Report on Form 10-K
for the year ended December 31, 2023, as filed with the Securities
and Exchange Commission (SEC) on March 14, 2024, and in any
subsequent filings with the SEC. The forward-looking statements
contained in this press release reflect Verastem Oncology’s views
as of the date hereof, and the Company does not assume and
specifically disclaims any obligation to update any forward-looking
statements whether as a result of new information, future events or
otherwise, except as required by law.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240418758500/en/
For Investor and Media Inquiries: Julissa Viana Vice
President, Corporate Communications and Investor Relations
investors@verastem.com or media@verastem.com
Verastem (NASDAQ:VSTM)
Historical Stock Chart
From Apr 2024 to May 2024
Verastem (NASDAQ:VSTM)
Historical Stock Chart
From May 2023 to May 2024